Our antibody development roots go deep
Light Chain Bioscience is a clinical-stage biotechnology company advancing therapies based on its proprietary bispecific antibody platform (κλ body)
κλ bodies fully retain the native structure of human IgG leading to low immunogenicity and improved safety in the clinic.
We enable unique mechanisms of action such as safe and selective CD47 targeting and tumor selective CD28 agonism to harness the immune system to treat cancer and other serious indications.
